



The Top Ten Global In-Vitro Diagnostics Companies

Positioning, performance and SWOT analyses

 [Table of Contents](#)

Copyright © 2009 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

The Top Ten Global In-Vitro Diagnostics Companies

Executive summary	16
Market Development	16
Roche Diagnostics	17
Siemens Healthcare	17
Abbott	18
J&J	19
Beckman Coulter	19
Becton Dickinson	20
bioMerieux	21
Bayer Diabetes	21
Sysmex	22
Bio Rad	23
Chapter 1 Introduction	26
What is this report about?	26
Methodology and definitions	26
Chapter 2 Market development	30
Summary	30
Overview	31
Market size and growth	31
Growth drivers	31
Key trends in the market	32
Industry consolidation	32
Convergence of IVD and In-vivo	32
Customer consolidation	33
Emergence of theranostics	33

Positioning and performance of top ten players	33
--	----

Chapter 3 Roche Diagnostics 38

Summary	38
Company overview	39
Group structure	39
Professional Diagnostics	39
Diabetes Care	39
Molecular Diagnostics	40
Applied Science	40
Recent financial performance	40
Performance by business segments (IVD)	42
Professional Diagnostics	42
Diabetes Care	42
Molecular Diagnostics	42
Performance by geographies	43
Acquisitions and divestments	44
Research and Development	45
Growth strategies	45
SWOT analysis	46
Strengths	46
Dominant market position	46
Diversified portfolio	47
Strong R&D facilities	47
Weaknesses	47
Slow growth of molecular diagnostics business	47
Opportunities	47
Molecular diagnostics market	47
Diabetes care and tissue diagnostics	48
Threats	48
Competition	48
Customer consolidation	48
Stringent regulations	49

Chapter 4 Siemens Healthcare 52

Summary	52
Company overview	53
Group structure	53
Recent financial performance	54

Acquisitions and divestments		55
Research and development		55
Growth strategies		56
SWOT analysis		57
Strengths		57
	Full suite of diagnostics offering	57
	Strong market position	58
	Strong brand name	58
Weaknesses		58
	Late entry into IVD	58
Opportunities		58
	Integrated offerings	58
	Molecular diagnostics market	59
Threats		59
	Competition	59
	Regulation	59

Chapter 5 Abbott 62

Summary		62
Company overview		63
Group structure		63
Recent financial performance		64
Performance by products		65
Performance by geographies		66
Acquisitions and divestments		66
Research and development		67
Growth strategies		67
SWOT analysis		68
Strengths		68
	Diversified revenue stream	68
	Strong performance of international diagnostics business	69
Weaknesses		69
	Declining margins	69
	Regulatory issues	69
	Sluggish top line growth in the domestic market	69
Opportunities		70
	Molecular diagnostics	70
	Diabetes care market	70
Threats		70
	Competition	70
	Regulatory environment	70

Chapter 6 Johnson & Johnson 72

Summary	72
Company overview	73
Group structure	73
Ortho-Clinical Diagnostics	73
Veridex	74
LifeScan	74
Recent financial performance	74
Performance by businesses	75
LifeScan	75
Ortho-Clinical Diagnostics	75
Veridex	76
Acquisitions and divestments	76
Growth strategies	77
Strategic partnerships	77
Acquisitions	77
SWOT analysis	78
Strengths	78
Strong market position	78
J&J brand	79
Strong topline growth	79
Weaknesses	79
Small contribution to J&J revenues	79
Opportunities	79
Amic acquisition	79
Diabetes monitoring market	80
Threats	80
Competition	80
Regulations	80

Chapter 7 Beckman Coulter (Beckman) 82

Summary	82
Company overview	83
Group structure	83
Clinical Diagnostics	84
Recent financial performance	84
Performance by geographies	85
Acquisitions and divestments	87
Research and Development	87
Growth strategies	88
Focus on immunoassay systems and molecular diagnostics	88

Expansion into emerging markets	89
SWOT analysis	89
Strengths	90
Global presence	90
Strong market position	90
Diverse product portfolio	90
Strong performance of immunoassay systems	90
Weaknesses	90
Late entry into molecular diagnostics	90
Lower operating margin	91
Opportunities	91
Emerging markets	91
Immunoassay systems	91
Threats	91
Consolidation of customers	91
Stiff competition	92

Chapter 8 Becton Dickinson (BD) 94

Summary	94
Company overview	95
Group structure	95
Preanalytical Systems	95
Diagnostic Systems	96
Recent financial performance	96
Performance by business segments	97
Preanalytical Systems	97
Diagnostics Systems	98
Acquisitions and divestments	98
Research and Development	98
Growth strategies	99
Strategic acquisitions	99
Organic growth measures	99
SWOT analysis	100
Strengths	101
Increased focus on Research and Development	101
Acquisition of TriPath and GeneOhm	101
Global presence	101
Weaknesses	101
Falling margins	101
Weak BGM business	101
Opportunities	102
HAI market	102
Cancer diagnostics market	102
Threats	102

Competition	102
Regulations	102

Chapter 9 bioMerieux 104

Summary	104
Company overview	105
Group structure	105
Clinical Diagnostics	105
Industrial Diagnostics	105
Recent financial performance	105
Performance by geographies	106
Acquisitions and divestments	107
Research and Development	108
Growth strategies	108
Geographic expansion	108
Infectious diseases and high-medical value tests	109
SWOT analysis	110
Strengths	110
Global presence	110
Strong R&D capabilities	111
Strong market position	111
Weaknesses	111
Weak performance of Immunoassay	111
Divestments	111
Opportunities	112
Emerging markets	112
Molecular Biology market	112
Threats	112
Competitive and pricing pressures	112
Regulatory environment	112

Chapter 10 Bayer Healthcare 114

Summary	114
Company overview	115
Group structure	115
Recent financial performance	115
Acquisitions and divestments	116
Growth strategies	117
SWOT analysis	118

Chapter 12 Bio Rad 136

Summary	136
Company overview	137
Group structure	137
Recent financial performance	137
Performance by geographies	139
Acquisitions and divestments	140
Research and Development	140
Growth strategies	141
Strategic acquisitions	141
New products	141
SWOT analysis	142
Strengths	142
Diversified revenues	142
Strong R&D focus	143
Strong revenue growth	143
Weaknesses	143
Limited product portfolio	143
Sluggish growth in Japan	143
Opportunities	143
DiaMed's acquisition	143
New products	144
Threats	144
Intense competition	144
Regulations	144

Chapter 13 Other leading players 146

Inverness	146
Company description	146
Recent financial performance	146
Chiron (Novartis Vaccines and Diagnostics)	148
Company description	148
Recent financial performance	148
Olympus	149
Company description	149
Recent financial performance	150
Gen Probe	151
Company description	151
Recent financial performance	151
Hologic / Cytoc	152
Company description	152

Recent financial performance	152
Qiagen	153
Company description	153
Recent financial performance	153
Arkray	154
Company description	154
DiaSorin	155
Company description	155
Recent financial performance	155
Radiometer	156
Company description	156
Recent financial performance	156
Werfen	157
Company description	157
Recent financial performance	158
Other major players	159
Index	160

List of Figures

Figure 2.1:	Global IVD market size and growth, 2007–2012	31
Figure 2.2:	Market share of Top 10 IVD companies, 2007	34
Figure 2.3:	Market positioning of top 10 IVD companies, 2007*	35
Figure 2.4:	Comparative Analysis of top 10 IVD companies	36
Figure 3.5:	Roche Diagnostics' financial performance (\$m), 2003-2007	41
Figure 3.6:	Roche Diagnostics' revenue break-up by geography (%), 2007	43
Figure 3.7:	Roche SWOT analysis	46
Figure 4.8:	Siemens Healthcare SWOT analysis	57
Figure 5.9:	Abbott's IVD financial performance (\$m), 2003-2007*	64
Figure 5.10:	Abbott's IVD revenue break-up by geography (%), 2007	66
Figure 5.11:	Abbott SWOT analysis	68
Figure 6.12:	J&J's IVD financial performance (\$m), 2003-2007	75
Figure 6.13:	J&J (IVD business) SWOT analysis	78
Figure 7.14:	Beckman's IVD financial performance (\$m), 2005-2007*	85
Figure 7.15:	Beckman's revenue break-up by geography (%), 2007*	86
Figure 7.16:	Beckman SWOT analysis	89
Figure 8.17:	BD Diagnostics' financial performance (\$m), 2005-2007*	97
Figure 8.18:	BD SWOT analysis	100
Figure 9.19:	bioMerieux's financial performance (\$m), 2003-2007*	106
Figure 9.20:	bioMerieux's revenue break-up by geography (%), 2007	107
Figure 9.21:	bioMerieux SWOT analysis	110
Figure 10.22:	Bayer Diabetes Care's financial performance (\$m), 2003-2007*	116
Figure 10.23:	Bayer Healthcare SWOT analysis	118
Figure 11.24:	Sysmex Diagnostics' financial performance (\$m), 2003-2007	124
Figure 11.25:	Sysmex's revenue break-up by geography (%), 2007	127
Figure 11.26:	Sysmex SWOT analysis	130
Figure 12.27:	Bio Rad Clinical Diagnostics' financial performance (\$m), 2003-2007	138
Figure 12.28:	Bio Rad's revenue break-up by geography (%), 2007*	139
Figure 12.29:	Bio Rad SWOT analysis	142

List of Tables

Table 2.1:	Top ten companies' revenue, profitability & growth (2003-2007)	35
Table 3.2:	Roche Diagnostics snapshot	39
Table 3.3:	Roche Diagnostics' financial performance (\$m), 2003-2007	41
Table 3.4:	Roche Diagnostics' IVD business segments performance (\$m),	43
Table 3.5:	Roche Diagnostics performance by geography (\$m), 2007*	44
Table 3.6:	Roche Diagnostics' R&D expenditure, 2006-2007	45
Table 4.7:	Siemens Healthcare snapshot	53
Table 4.8:	Siemens Healthcare Diagnostics' product segments performance (\$m), 2007	54
Table 4.9:	Siemens Healthcare Diagnostics' geographic performance (\$m),	55
Table 5.10:	Abbott snapshot	63
Table 5.11:	Abbott's IVD financial performance (\$m), 2003-2007	65
Table 5.12:	Abbott' IVD product segments performance (\$m),	65
Table 5.13:	Abbott's IVD performance by geography (\$m), 2005-2007	66
Table 6.14:	J&J snapshot	73
Table 6.15:	J&J's IVD financial performance (\$m), 2003-2007	75
Table 6.16:	J&J's IVD businesses performance (\$m), 2005-2007	76
Table 7.17:	Beckman snapshot	83
Table 7.18:	Beckman's IVD financial performance (\$m), 2005-2007	85
Table 7.19:	Beckman's performance by geography (\$m), 2005-2007	87
Table 7.20:	Beckman's R&D expenditure, 2005-2007	88
Table 8.21:	BD snapshot	95
Table 8.22:	BD Diagnostics' financial performance (\$m), 2005-2007	97
Table 8.23:	BD Diagnostics' business segments performance (\$m),	98
Table 8.24:	BD Diagnostics' R&D expenditure, 2006-2007	99
Table 9.25:	bioMerieux snapshot	104
Table 9.26:	bioMerieux's financial performance (\$m), 2003-2007	106
Table 9.27:	bioMerieux's R&D expenditure, 2005-2007	108
Table 10.28:	Bayer Healthcare snapshot	114
Table 10.29:	Bayer Diabetes Care's financial performance (\$m), 2003-2007	116
Table 11.30:	Sysmex snapshot	123
Table 11.31:	Sysmex Diagnostics' financial performance (\$m), 2003-2007	125
Table 11.32:	Sysmex Diagnostics' product segments performance (\$m),	125
Table 11.33:	Sysmex's performance by geography (\$m), 2005-2007	127
Table 11.34:	Sysmex's R&D expenditure, 2005-2007	128
Table 12.35:	Bio Rad snapshot	136
Table 12.36:	Bio Rad Clinical Diagnostics' financial performance (\$m), 2003-2007	138
Table 12.37:	Bio Rad's performance by geography (\$m), 2005-2007	139
Table 12.38:	Bio Rad's R&D expenditure, 2005-2007	140
Table 12.39:	Inverness snapshot	146
Table 12.40:	Inverness's IVD financial performance (\$m), 2003-2007	147
Table 12.41:	Chiron snapshot	148
Table 12.42:	Novartis Vaccines and Diagnostics' financial performance (\$m), 2006-2007*	149
Table 12.43:	Olympus snapshot	149
Table 12.44:	Olympus' IVD financial performance (\$m), 2003-2007	150
Table 12.45:	Gen Probe snapshot	151
Table 12.46:	Gen Probe's financial performance (\$m), 2003-2007	152

Table 12.47:	Hologic snapshot	152
Table 12.48:	Hologic Diagnostics' financial performance (\$m), 9months 2008	153
Table 12.49:	Qiagen snapshot	153
Table 12.50:	Qiagen's financial performance (\$m), 2003-2007*	154
Table 12.51:	Arkray snapshot	154
Table 12.52:	DiaSorin snapshot	155
Table 12.53:	DiaSorin's financial performance (\$m), 2003-2007	155
Table 12.54:	Radiometer snapshot	156
Table 12.55:	Danaher Medical Technologies' financial performance (\$m), 2005-2007*	157
Table 12.56:	Werfen snapshot	157
Table 12.57:	Werfen's financial performance (\$m), 2003-2007*	158
Table 12.58:	Other major players	159